Sophie Kervyn

发表

A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers

R. P. Maguire, P. Muglia, Yiyun Huang, 2019, Epilepsia.

Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A

R. P. Maguire, Yiyun Huang, R. Carson, 2022, EJNMMI Research.

Science‐Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels

K. Turner, C. Bowman, K. Thompson, 2022, Clinical pharmacology and therapeutics.

N-alkylprotoporphyrin formation and hepatic porphyria in dogs after administration of a new antiepileptic drug candidate: mechanism and species specificity.

J. Nicolas, L. Staelens, O. Depelchin, 2014, Toxicological sciences : an official journal of the Society of Toxicology.

Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action

Richard E Carson, Nabeel Nabulsi, Daniel Holden, 2016, Epilepsia.

Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative.

M. Traebert, Laura Breidenbach, K. Hempel, 2020, Journal of pharmacological and toxicological methods.

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment

M. Wood, Y. Lamberty, R. Kaminski, 2016, Epilepsia.

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.

Sally Robinson, Kathryn Chapman, David Dreher, 2008, Regulatory toxicology and pharmacology : RTP.

Reprint of: Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative.

M. Traebert, Laura Breidenbach, K. Hempel, 2020, Journal of pharmacological and toxicological methods.

Challenging the regulatory requirement for conventional acute toxicity studies in pharmaceutical drug development

David Dreher, Kathryn L Chapman, S. Robinson, 2007 .

A global pharmaceutical company initiative: an evidence-based approach to define the upper limit of body weight loss in short term toxicity studies.

Fiona Sewell, Sally Robinson, Kathryn Chapman, 2013, Regulatory toxicology and pharmacology : RTP.

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.

David Dreher, Kathryn L Chapman, M. Festag, 2008, Regulatory toxicology and pharmacology : RTP.